We are live on ! Find out more
Macquarie Group

Macquarie Group Portfolio holdings

AUM $16.8B
1-Year Est. Return 27.39%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+27.39%
3 Year Est. Return
+81.07%
5 Year Est. Return
+109.03%
10 Year Est. Return
+396.55%
AUM
$56.6B
AUM Growth
+$810M
Cap. Flow
-$1.48B
Cap. Flow %
-2.61%
Top 10 Hldgs %
13.48%
Holding
2,531
New
387
Increased
823
Reduced
1,010
Closed
163

Top Buys

Rank Stock Value
1
CME icon
CME Group
CME
+$94.6M
2
AMAT icon
Applied Materials
AMAT
+$91.8M
3
ANET icon
Arista Networks
ANET
+$73.5M
4
ILMN icon
Illumina
ILMN
+$50.4M
5
TV icon
Televisa
TV
+$49.9M

Top Sells

Rank Stock Value
1
MRO
Marathon Oil Corporation
MRO
+$149M
2
DLTR icon
Dollar Tree
DLTR
+$140M
3
INTC icon
Intel
INTC
+$129M
4
NVDA icon
NVIDIA
NVDA
+$104M
5
NLSN
Nielsen Holdings plc
NLSN
+$84.8M

Sector Composition

Rank Sector Weight
1 Healthcare 15.88%
2 Financials 15.63%
3 Technology 12.66%
4 Energy 10.4%
5 Industrials 9.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
2276
DELISTED
Astria Therapeutics
ATXS
$8K ﹤0.01%
+87
New +$10.2K
BANC icon
2277
Banc of California
BANC
$3.28B
$8K ﹤0.01%
400
-66,900
-99% -$1.4M
CLDX icon
2278
Celldex Therapeutics
CLDX
$2.77B
$8K ﹤0.01%
+193
New +$8.27K
CPRX
2279
DELISTED
Catalyst Pharmaceutical
CPRX
$8K ﹤0.01%
+2,100
New +$6.94K
CRIS icon
2280
Curis
CRIS
$9.53M
$8K ﹤0.01%
+6
New +$14.1K
GLMD icon
2281
Galmed Pharmaceuticals
GLMD
$3.94M
$8K ﹤0.01%
+5
New +$7.39K
GYRE icon
2282
Gyre Therapeutics
GYRE
$662M
$8K ﹤0.01%
+80
New +$4.08K
INDP icon
2283
Indaptus Therapeutics
INDP
$348M
$8K ﹤0.01%
+1
New +$15.5K
ING icon
2284
ING
ING
$93.8B
$8K ﹤0.01%
448
– –
LCTX icon
2285
Lineage Cell Therapeutics
LCTX
$257M
$8K ﹤0.01%
+4,343
New +$9.48K
PLUR icon
2286
Pluri
PLUR
$19.2M
$8K ﹤0.01%
+76
New +$9.49K
TOVX icon
2287
Theriva Biologics
TOVX
$10.2M
$8K ﹤0.01%
+2
New +$12.5K
TPST icon
2288
Tempest Therapeutics
TPST
$14.8M
$8K ﹤0.01%
+2
New +$8.39K
TRAW icon
2289
Traws Pharma
TRAW
$7.43M
$8K ﹤0.01%
+1
New +$10.3K
RNTX
2290
Rein Therapeutics
RNTX
$67.7M
$8K ﹤0.01%
+40
New +$9.59K
VIVS
2291
VivoSim Labs
VIVS
$1.46M
$8K ﹤0.01%
+24
New +$8.92K
ALPN
2292
DELISTED
Alpine Immune Sciences Inc
ALPN
$8K ﹤0.01%
+700
New +$7.62K
TTOO
2293
DELISTED
T2 Biosystems, Inc
TTOO
– –
0
– –
NVTA
2294
DELISTED
Invitae Corporation
NVTA
$8K ﹤0.01%
+900
New +$8.07K
BIOC
2295
DELISTED
Biocept, Inc.
BIOC
$8K ﹤0.01%
+1
New +$7.91K
JNCE
2296
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$8K ﹤0.01%
600
-7,368
-92% -$108K
MYOV
2297
DELISTED
Myovant Sciences Ltd.
MYOV
$8K ﹤0.01%
+600
New +$8.04K
ALBO
2298
DELISTED
Albireo Pharma Inc
ALBO
$8K ﹤0.01%
+300
New +$7.61K
GNMX
2299
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8K ﹤0.01%
+7,058
New +$9.63K
ACHN
2300
DELISTED
Achillion Pharmaceuticals
ACHN
$8K ﹤0.01%
+2,900
New +$10.5K
90 91
92
93 94

Similar funds

AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Macquarie Group's Q4 2017 Portfolio in Review

As of Q4 2017, Macquarie Group held 2,531 positions worth $56.6B, up 1.5% from $55.7B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Macquarie Group's Q4 2017 filing shows 387 new, 823 increased, 1,010 reduced and 163 closed positions. Its largest new stake was WPP: 343,817 shares worth $31.1M. The largest sale was Marathon Oil Corporation, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 16% a quarter earlier, followed by Financials and Technology.

  • Macquarie Group's largest Q4 2017 buy was WPP: 343,817 shares worth $31.1M.
  • Macquarie Group added most to CME Group in Q4 2017, an estimated $94.6M increase.
  • Macquarie Group's biggest Q4 2017 reduction was Marathon Oil Corporation, cutting an estimated $149M.
  • Macquarie Group fully exited Alexander & Baldwin in Q4 2017, selling an estimated $30.1M.
  • Macquarie Group's ten largest holdings make up 13% of its $56.6B portfolio in Q4 2017.
  • Macquarie Group opened 387 new positions and closed 163 in Q4 2017.
  • Macquarie Group's portfolio value rose 1.5% quarter-over-quarter to $56.6B.

Based on Macquarie Group's 13F filing for Q4 2017, filed 15 Feb 2018.